Study on the Hepatotoxicity of Emodin and Its Application in the Treatment of Liver Fibrosis
Molecules · 30.10.2024 · 29 (21) · 5122
DOI: 10.3390/molecules29215122 ↗Kurz gefasst
Fachartikel in der Zeitschrift Molecules, online erschienen am 30.10.2024. Verfasst von Yurou Guo und 6 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory of Southwestern Chinese Medicine Resources, Chengdu University of Traditional Chinese Medicine, Chengdu 611137, China. Hauptthemen laut MEDLINE: Emodin, Zebrafish, Liver Cirrhosis, Nanoparticles. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 55 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: the Sichuan Science and Technology Program, Xinglin Postdoctoral Foundation of Chengdu University of TCM, Sichuan Science and Technology Program.
Abstract (Originalsprache)
Emodin (EMO) is an anthraquinone compound derived from Rheum palmatum L., which has rich pharmacological activity. However, studies have shown that EMO may cause hepatotoxicity. In this study, EMO was combined with tetrandrine and prepared as lipid nanoparticles (E-T/LNPs). The anti-liver fibrosis activity of EMO before and after formulation was evaluated by zebrafish and mice. In addition, the toxicity of EMO and E-T/LNPs was compared and the toxicity–efficacy concentrations of E-T/LNPs in zebrafish were verified. E-T/LNPs are morphologically stable (particle size within 100 nm), have high encapsulation efficiency and good stability, and are capable of long-lasting slow release in vitro. The combination and preparation can reduce the toxicity and enhance the effect of EMO, and increase the toxicity and effect concentration of E-T/LNPs in vivo. In a short period, low doses of E-T/LNPs can be used for the treatment of liver fibrosis; high doses of E-T/LNPs cause toxicity in vivo. Immunohistochemistry showed that E-T/LNPs inhibited hepatic fibrosis by downregulating the levels of IL-1β and TGF-β. Based on the advantages of combination therapy and nanotechnology, it can play a role in reducing the toxicity and increasing the efficacy of EMO in the treatment of liver fibrosis.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- State Key Laboratory of Southwestern Chinese Medicine Resources, Chengdu University of Traditional Chinese Medicine, Chengdu 611137, China.
- School of Pharmacy, Chengdu University of Traditional Chinese Medicine, Chengdu 611137, China.
ORCID-Profile: Yiping Guo, Li Guo
Förderung
- the Sichuan Science and Technology Program
- Xinglin Postdoctoral Foundation of Chengdu University of TCM
- Sichuan Science and Technology Program
Zitieren
APA
Guo, Y., Song, J., Liu, Y., Yuan, M., Zhong, W., Guo, Y., & Guo, L. (2024). Study on the Hepatotoxicity of Emodin and Its Application in the Treatment of Liver Fibrosis. Molecules, 29(21), 5122. https://doi.org/10.3390/molecules29215122
Vancouver
Guo Y, Song J, Liu Y, Yuan M, Zhong W, Guo Y, et al. Study on the Hepatotoxicity of Emodin and Its Application in the Treatment of Liver Fibrosis. Molecules. 2024;29(21):5122. doi:10.3390/molecules29215122
BibTeX
@article{Guo2024,
author = {Guo, Yurou and Song, Jiawen and Liu, Yushi and Yuan, Minghao and Zhong, Wenxiao and Guo, Yiping and Guo, Li},
title = {Study on the Hepatotoxicity of Emodin and Its Application in the Treatment of Liver Fibrosis},
journal = {Molecules},
year = {2024},
volume = {29},
number = {21},
pages = {5122},
doi = {10.3390/molecules29215122}
}
EUVIMED